1. Record Nr. UNINA9910795438203321

Autore	Pasachoff Naomi E.
Titolo	Marie Curie and the science of radioactivity / / Naomi Pasachoff
Pubbl/distr/stampa	New York, New York ; ; Oxford : , : Oxford University Press, , 1997
ISBN	0-19-802525-4
Descrizione fisica	1 online resource (113 pages)
Collana	Oxford portraits in science
Disciplina	540.92
Soggetti	Chemists - Poland Women
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Sommario/riassunto	Marie Curie discovered radium and went on to lead the scientific community in studying the theory behind and the uses of radioactivity. She left a vast legacy to future scientists through her research, her teaching, and her contributions to the welfare of humankind. She was the first person towin two Nobel Prizes, yet upon her death in 1934, Albert Einstein was moved to say, "Marie Curie is, of all celebrated beings, the only one whom fame has not corrupted." She was a physicist, a wife and mother, and a groundbreaking professional woman. This biography is an inspirational and exciting story of scientific discovery and personal commitment.

2. Record Nr. UNINA9910793388703321

Autore	Klimo Arpad von
Titolo	Remembering cold days : the 1942 massacre of Novi Sad, Hungarian politics, & society, 1942-1989 / / Arpad von Klimo
Pubbl/distr/stampa	Pittsburgh, Pennsylvania : , : University of Pittsburgh Press, , [2018] ©2018
ISBN	0-8229-8609-4
Edizione	[1st ed.]
Descrizione fisica	1 online resource (xii, 268 pages) : illustrations, map
Collana	Pitt series in Russian and East European studies
Disciplina	943.9052
Soggetti	War and civilization - Hungary Hungarians - Yugoslavia
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Intro -- Contents -- Acknowledgments -- Introduction -- Part I. Violence and Revenge, 1942-1948 -- Chapter 1.The 1942 Massacre of Novi Sad -- Chapter 2. "Disloyalty": The Budapest Military Trial and the Holocaust -- Chapter 3. Revenge: The First Postwar Trials -- Part II. From Silencing to Site of Memory, 1949-1989 -- Chapter 4. Postwar: The Long Stalinist Decade -- Chapter 5. Fascists with a Human Face? The 1960s Novel and Film Cold Days -- Chapter 6. The Victims of Mass Violence and the End of the Communist Regime -- Epilogue -- Notes -- Bibliography -- Index.
Sommario/riassunto	"In Remembering Cold Days, von Klimo examines public contentions over the Novi Sad massacre from its inception in 1942 until the final trial in 2011, and reveals how attitudes changed over time toward this war crime and the Holocaust through different political regimes and in Hungarian society. The book also views how the larger European context influenced Hungarian debates, and how Yugoslavia dealt with memories of the massacre."

3. Record Nr. UNINA9911019125503321

Autore	Mussen Filip
Titolo	Benefit-risk appraisal of medicines : a systematic approach to decision making / / Filip Mussen, Sam Salek, Stuart Walker
Pubbl/distr/stampa	Chichester, West Sussex, UK ; ; Hoboken, NJ, : John Wiley & Sons, 2009
ISBN	9786612259494 9781282259492 1282259490 9780470748114 0470748117 9780470748121 0470748125
Descrizione fisica	1 online resource (306 p.)
Altri autori (Persone)	SalekSam WalkerStuart R. <1944->
Disciplina	615.19 615/.1901
Soggetti	Drugs - Testing Pharmaceutical policy - Decision making
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Benefit-Risk Appraisal of Medicines; Contents; Foreword; Preface; 1 Concept and Scope of Benefit-Risk Evaluation of Medicines; 1.1 Historical background; 1.2 The regulatory systems for assessing medicines; 1.3 Benefit-risk assessment: definitions; 1.4 Views and perceptions of benefits and risks of medicines; 1.5 Stages and concepts in benefit-risk assessment; 1.6 Benefit-risk assessment: the current regulatory environment; 1.7 Benefit-risk assessment in other disciplines; 1.8 Specific methods and models for benefit-risk assessment 1.9 Discussions with stakeholders on the concepts and models for benefit-risk evaluation2 Criteria for a Benefit-Risk Model: a Conceptual Framework; 2.1 Introduction; 2.2 Regulatory guidelines on benefit and risk criteria; 2.3 Identification, definition and rationale of relevant benefit and risk criteria; 2.4 Verification of the list of benefit and risk

criteria by means of a survey; 3 Review of the Current Benefit-Risk Assessment Models; 3.1 Background; 3.2 Evaluation of the existing benefit-risk assessment models; 3.3 Review of models in single clinical trials and for specific medicines
3.4 Conclusion3.5 Newer models; 4 Defining a Systematic Approach to Decision Making; 4.1 Introduction; 4.2 Objectives and features of the ideal model for benefit-risk assessment; 4.3 The use of decision-analysis techniques for the development of the new model; 5 Development and Application of a Benefit-Risk Assessment Model Based on Multi-Criteria Decision Analysis; 5.1 Introduction; 5.2 Conceptualization of the new model; 5.3 Reasons for using decision analysis techniques in the new model; 5.4 The use of MCDA in the new model; 5.5 Development of the new model
5.6 Applicability of the new model5.7 Summary; 5.8 Review of the MCDA model; 6 A Future Framework for Benefit-Risk Appraisal of Medicines; 6.1 Background; 6.2 Development of a benefit-risk framework for regulatory review of new medicines; 6.3 Prerequisites of a benefit-risk framework for the registration of a new medicine; 6.4 Current status of benefit-risk assessment among companies and agencies; 6.5 Constructing a benefit-risk framework; 6.6 Conclusion; Appendices
Appendix 1 Summary Reports of the CMR International Institute for Regulatory Science March 2004 and June 2005 Workshops on Benefit-RiskAppendix 2 Office of Health Economics Briefing: Challenges and Opportunities for Improving Benefit-risk Assessment of Pharmaceuticals from an Economic Perspective - James Cross and Louis Garrison (August 2008); Appendix 3 Reflection Paper on Benefit-risk Assessment Methods in the Context of the Evaluation of Marketing Authorisation Applications of Medicinal Products for Human Use - Committee for Medicinal Products for Human Use (March 2008)
Appendix 4 Commentaries on 'A Quantitative Approach to Benefit-risk Assessment of Medicines' Pharmacoepidemiology and Drug Safety, 2007, 16

Sommario/riassunto

Benefit-risk assessment is at the centre of the approval process for every new medicine. The ability to assess the risks of a new medicine accurately and to balance these against the benefits the medicine could bring is critical for every regulatory authority and pharmaceutical company. Despite this there are very few tried and tested evaluative models currently available. The authors of this book have developed a new, pioneering tool for the assessment of benefits and risks for new medicines in development. This model utilises a multi-criteria decision analysis which involves selecting,